AzTrials
AzTrials

Cardiovascular DiseasesMOVE-MINCT05193175

Effects of Breaking up Sitting Time on Cardiometabolic Risk Markers and Cardiac Function Post Myocardial Infarction

A study testing Prolonged sitting in people with Cardiovascular Diseases, run by University of Bedfordshire at 1 site in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Cardiovascular Disease (CVD) is one of the greatest causes of mortality and morbidity globally, particularly in middle to high income countries. In the UK alone, it was accountable for 124,641 deaths in 2017. Read more about this study

Who is it for?
Ages 40 years and older
Conditions the study is for
Cardiovascular Diseases
What is being tested?
Prolonged sitting
Could I receive a placebo?
No, everyone receives an active treatment
How many people
18 participants
Where
1 siteUnited Kingdom
Study dates
29 Nov 2021to 1 Jun 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients post myocardial infarction (ST wave elevated MI or Non-ST wave elevated MI) within the past three months (confirmed by elevated blood biomarkers or electrocardiographic changes), in which the procedure/ recovery uncomplicated and are therefore classified as low risk.
  • Aged 40 years or above.
  • Any ethnicity.
  • Individuals with diet controlled type 2 diabetes mellitus

Who cannot join

  • Previous MI
  • Under 40 years of age.
  • Unable to provide valid informed consent (lack of mental capacity).
  • Not had a cardiac event diagnosed within the past three months.
  • Existing comorbidities including cancer, chronic kidney disease and gastro-oesophageal diseases.
  • Unstable coronary disease.
Show all 9Show fewer
  • Diagnosed diabetes and use of medication.
  • Disease or conditions with a prognosis of less than 6 months to end of life (palliative care). Any known blood borne disease.
  • Unable to stand and engage in light-intensity stepping.

Trial locations and contacts

1 site in 1 country.

Joanna Richards, PhD contact

01234400400

jo.richards@beds.ac.uk

United Kingdom1 site, 1 recruiting
  • Cardiac Rehabilitation

    Bedford, Bedfordshire, MK429DJ

    Abbie Bell, MSc, 07984545911, abbie.bell@study.beds.ac.uk

    Joanna Richards, PhD, 01234 400400, jo.richards@beds.ac.uk

    Recruiting

Other trials in United Kingdom

About this study

Cardiovascular Disease (CVD) is one of the greatest causes of mortality and morbidity globally, particularly in middle to high income countries. In the UK alone, it was accountable for 124,641 deaths in 2017. Further to this, CVD contributes to a vast economic burden, costing the National Health Service (NHS) £19billion annually. This is mainly due to a significant number of hospital readmissions following a first cardiac event (198,000 per annum).

Following a cardiac event, an individual is therefore recommended to reduce their risk factors, including lipid profile, smoking status and physical inactivity, to reduce their risk of a secondary event. In healthy individuals, regularly breaking up sitting time reduces cardiometabolic risk markers. The aim of this study is to therefore observe if this effect is replicated in the cardiac population and thus whether breaking up sitting time will reduce the risk of a secondary cardiac event.

Read more

Potential participants will be required to meet an inclusion criteria to take part in the study: aged 50 years or above and had a myocardial infarction within the past three months at the time of recruitment to the study.

Participants will be randomised to each condition: 1) uninterrupted sitting; 2) sitting with intermittent standing and 3) sitting with intermittent light physical activity (stepping to a metronome beat). A number of physiological markers will be measured before, during and after each condition and analysed to compare the effectiveness of each condition.

All measurements will be taken at the University of Bedfordshire Sport and Exercise Science Laboratories.

Read the detailed description

Study design A repeated measures, randomised cross over study design will be used. All data collection will take place at the Sport and Exercise Science Laboratories, University of Bedfordshire, Polhill Avenue, Bedford, UK. After a preliminary testing session, participants will complete three, 6-hour experimental conditions in a random order: 1) uninterrupted sitting; 2) sitting interrupted with standing breaks, and 3) sitting interrupted with light intensity stepping breaks. There will be a washout period of at least 72 hours between conditions, as previous research suggests that a single session of exercise can affect blood glucose levels for the following 48 hours (Mikines, et al., 1988). Participants will be randomised to order of condition using computer generated random numbers. This will assign them a trial order using block randomization with balanced block sizes. Participants will be blinded to the trial condition until they arrive on the day of their first and second experimental conditions.

Preliminary testing Patients will first attend a preliminary testing session where they will become accustomed to light intensity stepping on the spot to the beat of a metronome and use of the Borg RPE scale. This will ensure patients are familiar with an intensity that is equivalent to an RPE of 8-11 (very light to light) that will be used in the respective experimental condition. Participants will step to different metronome paces starting at a slow pace and building up gradually every 1-2 minutes until an RPE of 8-11 is found. This imitates the intensity recommended within the warm up of CR, as recommended by BACPR. Height (cm) and weight (kg) will also be measured using a stadiometer (Harpenden 98.602, Holtain Ltd., Crymych) and digital scales (Tanita BWB0800, Tanita Corp., Tokyo, Japan) respectively, to calculate body mass index (kg/m2).

Experimental Protocol Participants will be asked to refrain from any alcohol and caffeine for 24 hours prior to each visit, as well as avoid exercise for 72 hours and complete an overnight fast. This will be explained to them during the preliminary visit. To monitor this, they will be asked prior to participation per visit whether they have fasted/ when they last ate and drank.

Participants will be asked to perform an overnight fast for at least 10 hours before arrival and minimise active travel to the laboratory (e.g. use a car for travel). They will rest for 30 minutes to achieve a steady state before baseline blood pressure (two measures with 2 minutes rest between each and the average taken) and blood samples are taken. Baseline cardiac function measures (global strain, ejection fraction and systolic volume) will be measured using an echocardiogram scan, as well as an electrocardiogram (ECG) to ensure there are no electrical contraindications to the heart which would make the participant unsuitable to complete the study intervention including ST depression / elevation or any arrythmias. Baseline mood and wellbeing measures will then be assessed using questionnaires.

Following baseline measures, a standardised breakfast will be consumed (see meals section below) and participants will then commence the experimental condition. See Figure 1 for schematic of experimental conditions.

The three experimental conditions for this study are:

  1. Uninterrupted sitting for 6 hours.
  2. Sitting interrupted with 5 minutes of static standing every 30 minutes.
  3. Sitting interrupted with 5 minutes of light intensity stepping every 30 minutes using a metronome at the intensity determined during preliminary testing. This replicates active recovery time currently performed in a phase III CR class.

A lunch meal will be provided at 12:00 during each condition. During sitting periods, participants will be able to read books, magazines or newspapers and/or watch TV, DVDs or media streaming services. Participants will be transported to the toilets and food consumption areas using a wheelchair to ensure activity is minimised and standardised between conditions.

Standardised food and water intake Each meal will provide approximately 30% of estimated daily energy requirements. This will be calculated for each individual participant using a prediction equation based on individual's height, weight and gender. Breakfast will consist of bran flakes, whole milk, and a honey and granola bar and will consist of 54% carbohydrate, 34% fat and 12% protein. Lunch will consist of a chicken sandwich, salted crisps and jammie dodger biscuit (54% carbohydrate, 34% fat and 12% protein). The macronutrient composition of the meals are in general agreement with guidelines recommended for a balanced diet (Public Health England, 2016). Participants will be encouraged to consume their meal within 15 minutes. The time taken will be recorded in the first condition and this time will then be replicated in the latter two conditions. Water will be available for the participants ad libitum during their first experimental condition visit. This volume of intake will be recorded and the same amount provided in the following two conditions spread over the day.

Data collection Finger prick capillary whole blood samples will be collected at baseline, 30, 60, 120, 180, 210, 240, 300 and 360 minutes throughout the conditions to allow later analysis of glucose, triglycerides, HDL-C, and insulin. Blood samples will be taken after the hand is pre-warmed in warm water for approximately 5 minutes. Blood pressure and heart rate will be measured 5 minutes before each of the blood samples are taken. Cardiac function measures and mood and wellbeing will be measured at baseline and post-condition.

Being tested
Prolonged sitting
Medical subject headings
Cardiovascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Prolonged sittingBehavioural

    Also called Sitting interrupted with standing, Sitting interrupted with light stepping

    Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping

Study groups in NCT05193175
Study groupRoleWhat they receive
Prolonged sittingExperimentalUninterrupted sitting for 6 hours.
Receives: Behavioral: Prolonged sitting
Sitting interrupted with standingExperimentalSitting interrupted with 5 minutes of static standing every 30 minutes for 6 hours.
Receives: Behavioral: Prolonged sitting
Sitting interrupted with light steppingExperimentalSitting interrupted with 5 minutes of light intensity stepping every 30 minutes using a metronome at the intensity determined during preliminary testing. This replicates active recovery time currently performed in a phase III CR class.
Receives: Behavioral: Prolonged sitting

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Posterior wall thickness

    Posterior wall thickness in cm

    Measured: 4 months

  2. Interventricular septum

    Interventricular septum in cm

    Measured: 4 months

  3. Left ventricular internal diameter

    Left ventricular internal diameter in cm

    Measured: 4 months

  4. Aortic root

    Aortic root in cm

    Measured: 4 months

  5. End volume

    End volume in cm

    Measured: 4 months

  6. E wave

    E wave in ms

    Measured: 4 months

  7. A wave

    A wave in ms

    Measured: 4 months

  8. Relative wall thickness

    Relative wall thickness in cm

    Measured: 4 months

  9. Left ventricular mass

    Left ventricular mass in g

    Measured: 4 months

  10. E/A ratio

    E/A ratio

    Measured: 4 months

  11. Deceleration time

    Deceleration time in ms

    Measured: 4 months

  12. Isovolumetric relaxation time

    Isovolumetric relaxation time in ms

    Measured: 4 months

  13. Ejection fraction

    Ejection fraction in %

    Measured: 4 months

  14. Stroke volume

    Stroke volume in L

    Measured: 4 months

Secondary outcomes (9)
  1. Systolic Blood pressure

    Resting systolic blood pressure in mmHg

    Measured: 4 months

  2. Diastolic Blood pressure

    Resting diastolic blood pressure in mmHg

    Measured: 4 months

  3. Postprandial triglycerides

    Postprandial triglycerides in mmol/L

    Measured: 4 months

  4. Postprandial total cholesterol

    Postprandial total cholesterol in mmol/L

    Measured: 4 months

  5. Postprandial low density lipoprotein cholesterol

    Postprandial low density lipoprotein cholesterol in mmol/L

    Measured: 4 months

  6. Postprandial high density lipoprotein cholesterol

    Postprandial high density lipoprotein cholesterol in mmol/L

    Measured: 4 months

  7. Postprandial insulin

    Postprandial insulin in mU/L

    Measured: 4 months

  8. Postprandial glucose

    Postprandial glucose in mmol/L

    Measured: 4 months

  9. Mood and wellbeing

    Positive affect and negative affect scale. This is a 5 point score, that asks 10 questions about positive feelings and 10 questions about negative feelings. The higher the score for each scale, the more likely they are feeling positive or negative.

    Measured: 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jan 2022
  2. Study start29 Nov 2021
  3. Primary completion30 Apr 2023 (estimated)
  4. Study completion1 Jun 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Participant
Enrolment
18 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05193175
Sponsor's protocol ID
265468
Acronym
MOVE-MI
Status last verified
Mar 2023
First submitted
6 Dec 2021
Last updated
3 Mar 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Upon registration to the study, participants will be given a unique participant ID number, which will henceforth be used in all data collection within the study. This will be determined using a number system. A confidential log will be kept by the research team to identify participants with their anonymous ID numbers, which will be encrypted on a secure computer. All other electronic documentation will also be encrypted. Only direct members of the research team will have access to the data, and will be listed on the study's delegation log. Where data is transmitted to sponsors, if necessary, it will only be identifiable by its participant ID number, thus not becoming patient identifiable at any time.

Questions about this trial

What is this clinical trial studying?

A study testing Prolonged sitting in people with Cardiovascular Diseases, run by University of Bedfordshire at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Abbie C Bell, MSc (07984545911, abbie.bell@study.beds.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Posterior wall thickness (time frame: 4 months). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in